Nutritional Supplements and Their Effect on Glucose Control
- 885 Downloads
Type 2 diabetes is a growing health concern. The use of nutritional supplements by patients with type 2 diabetes is estimated at somewhere between 8% to 49%. The objective of this review was to search the scientific literature for advances in the treatment and prevention of type 2 diabetes with nutritional supplements. Twelve databases were searched with a focus on extracting studies published in the past 3 years. The following nutritional supplements were identified as potentially beneficial for type 2 diabetes treatment or prevention: vitamins C and E, α-lipoic acid, melatonin, red mold, emodin from Aloe vera and Rheum officinale, astragalus, and cassia cinnamon. Beta-carotene was shown to be ineffective in the prevention of type 2 diabetes. Ranging from preclinical to clinical, there is evidence that nutritional supplements may be beneficial in the treatment or prevention of type 2 diabetes. Health providers should investigate drug-nutritional supplement interactions prior to treatment.
KeywordsDiabetes Diabetes mellitus Non-insulin-dependent diabetes T2D DM Nutrition Nutritional supplements Dietary supplements Natural health products NHP CAM Complementary in alternative medicine α-Lipoic acid ALA Coenzyme Q10 Vitamin E Chromium Cinnamon Emodin Red mold Astragalus
Conflicts of interest: T. Lee: none; J-J Dugoua: has received grant support from New Chapter, has received honoraria from Celt Naturals, and has stock in Newtopia, Inc.
Papers of particular interest, published recently, have been highlighted as: •• Of major importance
- 1.WHO. Fact Sheet #312: Diabetes. 2009.Google Scholar
- 10.Chang YC, Chuang LM. The role of oxidative stress in the pathogenesis of type 2 diabetes: from molecular mechanism to clinical implication. Am J Transl Res;2(3):316–31.Google Scholar
- 15.Hoeldtke RD, Bryner KD, Vandyke K. Oxidative stress and autonomic nerve function in early type 1 diabetes. Clin Auton Res 2010 Sep 25. [Epub ahead of print].Google Scholar
- 25.•• Heinisch BB, Francesconi M, Mittermayer F, Schaller G, Gouya G, Wolzt M, et al. Alpha-lipoic acid improves vascular endothelial function in patients with type 2 diabetes: a placebo-controlled randomized trial. Eur J Clin Invest 2010;40(2):148–54. This new RCT trial is another step toward the promise of ALA as a staple treatment for T2D. The positive effects of ALA on vascular blood flow highlights yet another mechanism by which ALA reduces the risk of cardiovascular events related to complications caused by T2D.PubMedCrossRefGoogle Scholar
- 28.Yi X, Nickeleit V, James LR, Maeda N. alpha-Lipoic acid protects diabetic apolipoprotein E-deficient mice from nephropathy. J Diabetes Complications 2010 Aug 26. [Epub ahead of print].Google Scholar
- 35.Peschke E, Frese T, Chankiewitz E, Peschke D, Preiss U, Schneyer U, et al. Diabetic Goto Kakizaki rats as well as type 2 diabetic patients show a decreased diurnal serum melatonin level and an increased pancreatic melatonin-receptor status. J Pineal Res 2006;40(2):135–43.PubMedCrossRefGoogle Scholar
- 36.•• Contreras-Alcantara S, Baba K, Tosini G. Removal of melatonin receptor type 1 induces insulin resistance in the mouse. Obesity (Silver Spring) 2010;18(9):1861–3. This preclinical study showed promising results for the future use of melatonin in the treatment of T2D. Imbalanced circadian rhythms should be considered an important factor in the development of T2D considering insulin is known to be highly influenced by these hormones, specifically growth hormone, and this study now outlines that melatonin may also be a potential regulator of insulin levels.CrossRefGoogle Scholar
- 46.Shi YC, Pan TM. Antioxidant and pancreas-protective effect of red mold fermented products on streptozotocin-induced diabetic rats. J Sci Food Agric 2010 Aug 24. [Epub ahead of print].Google Scholar
- 57.•• Crawford P. Effectiveness of cinnamon for lowering hemoglobin A1C in patients with type 2 diabetes: a randomized, controlled trial. J Am Board Fam Med 2009;22(5):507–12. This RCT is the first clinical study to demonstrate that cassia cinnamon can reduce glycosylated HbA 1c . Measurements between baseline and end point were taken at 90 days, which is the minimum time needed to observe a clinical change in HbA 1c.PubMedCrossRefGoogle Scholar
- 59.Huseini HF, Larijani B, Heshmat R, Fakhrzadeh H, Radjabipour B, Toliat T, et al. The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial. Phytother Res 2006;20(12):1036–9.PubMedCrossRefGoogle Scholar